XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues $ 131,840 $ 98,267
Cost of products sold 102,440 73,625
Gross profit 29,400 24,642
Operating expenses:    
Research and development 7,081 6,826
Selling, general and administrative 22,190 17,781
Total operating expenses 29,271 24,607
Operating income 129 35
Other expense (income):    
Interest and financing expense 951 242
Miscellaneous income (376) (56)
Total other expense, net 575 186
Loss before income taxes (446) (151)
Income tax (benefit) provision (326) 79
Net loss (120) (230)
Net (loss) income attributable to non-controlling interest (1) 4
Loss attributable to Ultralife Corporation (119) (234)
Other comprehensive (loss) income:    
Foreign currency translation adjustments (2,097) 129
Comprehensive loss attributable to Ultralife Corporation $ (2,216) $ (105)
Net loss per share attributable to Ultralife Corporation common shareholders – Basic (in dollars per share) $ 0.03 $ 0.05
Net loss per share attributable to Ultralife Corporation common shareholders – Diluted (in dollars per share) $ 0.03 $ 0.05
Weighted average shares outstanding – Basic (in shares) 16,125 16,037
Weighted average shares outstanding – Diluted (in shares) 16,125 16,037